John P. Hamill, Senior VP/CFO/Prin Fin & Acct Ofcr at Aprea Therapeutics, Inc. (APRE), bought 5,700 shares at $0.89 ($5K) on 2026-01-30, disclosed to the SEC on 2026-02-02.
Open-market purchase of $5k APRE by Senior VP/CFO/Prin Fin & Acct Ofcr. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Clearly above the average filing.
| Filing → |
| APRE | BUY | 2024-10-15 | $1K | — | Filing → |
| APRE | BUY | 2024-03-14 | $7K | — | Filing → |
| WINT | BUY | 2022-07-26 | $1K | — | Filing → |